These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 22309109)

  • 1. Functional reconstitution of defective myeloid dendritic cells in chronic hepatitis C infection on successful antiviral treatment.
    Rana D; Chawla YK; Duseja A; Dhiman R; Arora SK
    Liver Int; 2012 Aug; 32(7):1128-37. PubMed ID: 22309109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monocyte-derived dendritic cells in children with chronic hepatitis C: correlation with interferon and ribavirin therapy.
    Khedr MA; E Behairy B; Hussein ME; Marei AM; Nage SA; Zakaria HM
    Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1170-4. PubMed ID: 26148246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional impairment of dendritic cells in patients infected with hepatitis C virus genotype 1 who failed peginterferon plus ribavirin therapy.
    Liang CC; Liu CH; Lin YL; Liu CJ; Chiang BL; Kao JH
    J Med Virol; 2011 Jul; 83(7):1212-20. PubMed ID: 21567425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dynamic changes in PD-1, TLR3, and TLR4 surface expression on peripheral blood mononuclear cells in chronic hepatitis C patients undergoing peg-IFNalpha-2a plus ribavirin combination therapy].
    Zhang M; Jiang YF; Xiao XQ; Liu SF; Peng ML; Liu D; Gong GZ
    Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):196-201. PubMed ID: 23967741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolation and functional analysis of circulating dendritic cells from hepatitis C virus (HCV) RNA-positive and HCV RNA-negative patients with chronic hepatitis C: role of antiviral therapy.
    Tsubouchi E; Akbar SM; Murakami H; Horiike N; Onji M
    Clin Exp Immunol; 2004 Aug; 137(2):417-23. PubMed ID: 15270861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired ability of interferon-alpha-primed dendritic cells to stimulate Th1-type CD4 T-cell response in chronic hepatitis C virus infection.
    Miyatake H; Kanto T; Inoue M; Sakakibara M; Kaimori A; Yakushijin T; Itose I; Miyazaki M; Kuzushita N; Hiramatsu N; Takehara T; Kasahara A; Hayashi N
    J Viral Hepat; 2007 Jun; 14(6):404-12. PubMed ID: 17501761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.
    Soresi M; Tripi S; Franco V; Giannitrapani L; Alessandri A; Rappa F; Vuturo O; Montalto G
    Liver Int; 2006 Nov; 26(9):1119-25. PubMed ID: 17032413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of dendritic cell frequency and function in virological relapse in pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C patients.
    Itose I; Kanto T; Inoue M; Miyazaki M; Miyatake H; Sakakibara M; Yakushijin T; Oze T; Hiramatsu N; Takehara T; Kasahara A; Katayama K; Kato M; Hayashi N
    J Med Virol; 2007 May; 79(5):511-21. PubMed ID: 17385691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The basal activation state of DC subsets correlates with anti-HCV treatment outcome in HCV/HIV co-infected patients.
    Sacchi A; Agrati C; D'Offizi G; Vlassi C; Rozera G; Abbate I; Capobianchi MR; Martini F
    Clin Immunol; 2011 Feb; 138(2):178-86. PubMed ID: 21130688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum interleukin-6 levels correlate with resistance to treatment of chronic hepatitis C infection with pegylated-interferon-α2b plus ribavirin.
    Ueyama M; Nakagawa M; Sakamoto N; Onozuka I; Funaoka Y; Watanabe T; Nitta S; Kiyohashi K; Kitazume A; Murakawa M; Nishimura-Sakurai Y; Sekine-Osajima Y; Itsui Y; Azuma S; Kakinuma S; Watanabe M;
    Antivir Ther; 2011; 16(7):1081-91. PubMed ID: 22024524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
    Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cells activation is associated with sustained virological response to telaprevir treatment of HCV-infected patients.
    Sacchi A; Tumino N; Turchi F; Refolo G; Fimia G; Ciccosanti F; Montalbano M; Lionetti R; Taibi C; D'Offizi G; Casetti R; Bordoni V; Cimini E; Martini F; Agrati C
    Clin Immunol; 2017 Oct; 183():82-90. PubMed ID: 28736275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of standard antiviral therapy retreatment following interferon treatment failure in chronic hepatitis C patients].
    Liu JP; Kang Y; Shang J; Ding GQ; Xiao EH; Wei JF; Cao Q
    Zhonghua Gan Zang Bing Za Zhi; 2013 Sep; 21(9):656-8. PubMed ID: 24160338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human leukocyte antigen alleles and the response to pegylated interferon/ribavirin therapy in chronic hepatitis C patients.
    Dai CY; Chuang WL; Hsieh MY; Huang JF; Lin YY; Chu PY; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
    Antiviral Res; 2010 Feb; 85(2):396-402. PubMed ID: 19931565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C.
    Carrión JA; Gonzalez-Colominas E; García-Retortillo M; Cañete N; Cirera I; Coll S; Giménez MD; Márquez C; Martin-Escudero V; Castellví P; Navinés R; Castaño JR; Galeras JA; Salas E; Bory F; Martín-Santos R; Solà R
    J Hepatol; 2013 Nov; 59(5):926-33. PubMed ID: 23811030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
    Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
    New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
    J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C.
    Villa E; Cammà C; Di Leo A; Karampatou A; Enea M; Gitto S; Bernabucci V; Losi L; De Maria N; Lei B; Ferrari A; Vukotic R; Vignoli P; Rendina M; Francavilla A
    J Viral Hepat; 2012 Sep; 19(9):640-9. PubMed ID: 22863268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C.
    Diago M; Castellano G; García-Samaniego J; Pérez C; Fernández I; Romero M; Iacono OL; García-Monzón C
    Gut; 2006 Mar; 55(3):374-9. PubMed ID: 16150856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.